Direct answer. AV nodal re-entrant tachycardia, or AVNRT, is a type of supraventricular tachycardia involving an electrical circuit near the AV node. Episodes can start and stop abruptly. An ECG or selected monitoring helps establish the rhythm; treatment and any at-home episode instructions should follow the confirmed diagnosis and clinical plan.
- AVNRT is a specific SVT mechanism, not a name for every fast pulse.
- Its re-entry circuit is near the AV node; it differs from WPW-related accessory-pathway tachycardia.
- An ECG during symptoms can be especially informative.
- Ablation and medicines are clinical options with different purposes and risks.
- Learn episode instructions from the treating team rather than performing online neck or pressure maneuvers.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| What makes it AVNRT? | GOSH SVT mechanisms, pediatric context | A re-entry circuit near the AV node, not every SVT mechanism. |
| What helps confirm an episode? | NHLBI arrhythmia diagnosis | Appropriate electrical recording, not symptoms alone. |
| Which treatment is best for everyone? | NHS supraventricular tachycardia | No universal choice is supplied; the diagnosis, episodes and preferences matter. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
The AV node normally helps transmit signals between the atria and ventricles. GOSH describes AVNRT as a circuit near that node involving tissue with different conduction properties. This differs from AV re-entrant tachycardia using an additional pathway between chambers, as can occur with WPW. GOSH SVT mechanisms, pediatric context; NHS Wolff–Parkinson–White syndrome.
AVNRT is one cause within the SVT umbrella. Palpitations, breathlessness or light-headedness may accompany a rapid episode, but those symptoms do not identify the circuit. The written diagnosis should name the mechanism where it has been established, rather than equate all fast rhythms. NHS supraventricular tachycardia.
How it works
Re-entry sustains an electrical impulse in a repeating circuit. The relevant question is where that circuit runs and how it affects the recorded rhythm. A narrow clinical tracing or an average pulse number has to be interpreted in the full setting; a consumer rate label cannot establish AVNRT. GOSH SVT mechanisms, pediatric context.
A patient with an abrupt episode may have a normal tracing between events. Recording duration and timing therefore matter. Clinicians can choose monitoring aimed at capturing an episode, or an electrophysiology study when an electrical investigation is appropriate. These tests answer different questions. NHLBI arrhythmia diagnosis.
The evidence-based treatments
NHS describes ECG and selected longer recording for SVT. Give the clinician an account of onset, duration, associated symptoms and recovery. Avoid provoking an episode to obtain a better recording, and follow any agreed plan about what data a home device can safely contribute. NHS supraventricular tachycardia.
Treatment of a current episode depends on the clinical situation and stability. Longer-term options can include prescribed medicines or catheter ablation. The purpose of ablation is to address the relevant circuit; the procedure requires a diagnosis and an explanation of its proposed benefit and complications. NHS supraventricular tachycardia.
Do not confuse targeted treatment of an AVNRT circuit with deliberate AV-node ablation for a different indication. A procedure’s exact name, target and consequences should be explained. The guide does not provide a success percentage or assume that every procedure near the AV node has the same outcome. NHLBI arrhythmia treatment.
GOSH’s page is dated and pediatric. Its general procedure figures are not used here as independent AVNRT efficacy estimates for adults or children. Any proposed ablation should come with the treating centre’s current information about the specific procedure, recurrence, risks and follow-up. GOSH SVT mechanisms, pediatric context.
Supplement and lifestyle evidence
Discuss individual triggers and safe activity with the care team. A general rhythm label is not enough to decide whether exercise, caffeine or another exposure should be restricted. Managing relevant heart disease and taking prescribed medicines appropriately can be part of the plan. NHLBI living with arrhythmia.
No supplement is established here as a treatment for AVNRT. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care names the circuit where confirmed, explains what the proposed treatment targets and gives an episode and follow-up plan. A lower resting rate and prevention of abrupt re-entry episodes are different outcomes.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Rapid palpitations with chest pain, severe breathlessness, fainting or major deterioration require urgent assessment. Collapse with abnormal breathing is an emergency. A familiar episode pattern is not a reason to ignore new warning features. NHS arrhythmia.
Medicines intended to change heart rate or rhythm can themselves cause troublesome symptoms or another rhythm problem. Procedures have risks that should be explained for the proposed intervention, including bleeding or damage associated with catheter procedures. The exact diagnosis, heart function and medicine combination matter. NHLBI arrhythmia treatment.
Important interactions
Rate- and rhythm-changing medicines should be reviewed in the context of the confirmed mechanism. Never borrow another person’s rescue drug or combine products based on a general SVT label. NHLBI arrhythmia treatment.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
People with recurring abrupt episodes or an uncertain SVT label should obtain the recommended rhythm evaluation. A recording that shows only the average rate does not establish whether AVNRT is responsible. NHLBI arrhythmia diagnosis.
A person with recurring symptoms needs a clear review route even when a brief earlier ECG was reassuring. Record the timing and circumstances for the clinician, rather than provoking another episode to prove what it is. NHLBI arrhythmia diagnosis.
Clinician-led use and follow-up
Ask what an episode plan should include, how recurrence will be reviewed and which symptoms change the urgency. After a procedure, clarify activity instructions, expected short-term symptoms and when another recording is warranted. NHLBI living with arrhythmia.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Cell and animal experiments on vessel function or cardiac stress can suggest mechanisms. They do not establish safe human dosing, symptom improvement or fewer serious events. A laboratory preparation and a retail product may differ in composition, absorption and exposure. No animal or in-vitro result contributes to the independent clinical verdict in this guide.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 9 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The financial stakes include ECG monitoring, electrophysiology services, antiarrhythmic medicines, implanted devices and ablation. Diagnostic yield, symptom relief and prevention of a serious event are distinct claims. No commercially supported efficacy result establishes the independent verdict in this guide.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| GOSH SVT mechanisms, pediatric context | GOSH NHS Foundation Trust’s 2025–26 audited accounts identify NHS commissioner income, private-patient income, research income and charitable capital/expenditure contributions; its overview also names commercial research. Actual clinical-page allocation, research sponsors and author financial chain remain unresolved. The national NHS website sponsorship policy is not assumed to cover this separate Trust site. | United Kingdom; Great Ormond Street Hospital for Children NHS Foundation Trust, London; pediatric public provider. | Tier 2 institutional service-fee/charity routes; full chain provisional. | B provisional for pediatric clinical context. Specialist public-service expertise supports accuracy; service incentives, age scope and unresolved donor or author ties limit inference. Role: Specific AVNRT mechanism, dated pediatric context; December 2020. |
| NHS supraventricular tachycardia | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: Current SVT assessment and care categories. |
| NHS Wolff–Parkinson–White syndrome | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: Accessory-pathway distinction. |
| NHLBI arrhythmia diagnosis | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: ECG, monitoring and electrophysiology roles. |
| NHLBI arrhythmia treatment | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Drug/procedure risks. |
| NHS arrhythmia | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: Urgent symptom context. |
| NHLBI living with arrhythmia | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Individual follow-up and activity planning. |
| NHLBI arrhythmias | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| GOSH audited annual accounts 2025–26 | GOSH NHS Foundation Trust’s 2025–26 audited accounts identify NHS commissioner income, private-patient income, research income and charitable capital/expenditure contributions; its overview also names commercial research. Actual clinical-page allocation, research sponsors and author financial chain remain unresolved. The national NHS website sponsorship policy is not assumed to cover this separate Trust site. | United Kingdom; Great Ormond Street Hospital for Children NHS Foundation Trust, London; pediatric public provider. | Tier 3 Trust financial self-disclosure. | B provisional. Audited institution accounts support stated revenue routes; page-level allocation, donors and all research sponsors were not cleared. Financial provenance only. |
Frequently asked questions
Is every SVT AVNRT?
No. SVT has several mechanisms. GOSH SVT mechanisms, pediatric context.
Is it the same circuit as WPW?
No. WPW involves an additional pathway between chambers. NHS Wolff–Parkinson–White syndrome.
Can a tracing be normal between episodes?
Yes; the monitoring strategy may need to address intermittent symptoms. NHLBI arrhythmia diagnosis.
Should I copy a neck maneuver from a video?
No. Episode instructions must be taught for the established diagnosis.
Sources and funding notes
- GOSH SVT mechanisms, pediatric context — Specific AVNRT mechanism, dated pediatric context; December 2020.
- NHS supraventricular tachycardia — Current SVT assessment and care categories.
- NHS Wolff–Parkinson–White syndrome — Accessory-pathway distinction.
- NHLBI arrhythmia diagnosis — ECG, monitoring and electrophysiology roles.
- NHLBI arrhythmia treatment — Drug/procedure risks.
- NHS arrhythmia — Urgent symptom context.
- NHLBI living with arrhythmia — Individual follow-up and activity planning.
- NHLBI arrhythmias — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- GOSH audited annual accounts 2025–26 — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. Where cited, the 2026 definition was read through the web tool; its author supplement was inaccessible and remains an explicit gap. Where cited, the 2018 SCAD papers were read in original full versions, including funding and disclosure tables. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.